# A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

> **NCT06732895** · PHASE2 · RECRUITING · sponsor: **Ascendis Pharma A/S** · enrollment: 24 (estimated)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** Navepegritide
- **DRUG:** Placebo for navepegritide

## Key facts

- **NCT ID:** NCT06732895
- **Lead sponsor:** Ascendis Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2027-08
- **Final completion:** 2027-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732895, "A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06732895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*